Drug Profile
Research programme: IgE monoclonal antibody therapeutics - OncoQuest
Alternative Names: anti-Her2/neu antibody; anti-PSA monoclonal IgE; Monoclonal IgE for solid tumor immunotherapy - Quest PharmaTechLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Advanced Immune Therapeutics
- Developer OncoQuest; University of California at Los Angeles
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; IgE receptor modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Prostate cancer; Solid tumours
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
- 27 Sep 2019 Preclinical development is still ongoing for Breast cancer and Prostate cancer in USA (Parenteral) (OncoQuest pipeline, September 2019)